MAIA Biotechnology, Inc.

08/14/2026

MAIA Biotechnology has been nominated for the 2026 Prix Galien USA Award in the Best Startup category!

We are proud of the recognition as we continue advancing our work in targeted cancer therapies and the clinical development of ateganosine.

Thank you to The Galien Foundation. We look forward to the Prix Galien USA Awards Ceremony this October.

Learn more: https://prn.to/4zvZ9fA

07/21/2026

Cancer cells rely on telomeres to continue dividing. What happens when that process is disrupted?

MAIA Biotechnology Chairman and CEO Dr. Vlad Vitoc joined The Big Biz Show to explain the biology behind ateganosine, including its dual mechanism of action designed to target cancer cells while activating immune responses.

Watch the interview:

Dr. Vlad Vitoc, Founder, CEO, Chairman, and President of MAIA Biote...

07/20/2026

Thank you to Benzinga for highlighting MAIA Biotechnology's latest Phase 2 THIO-101 clinical update, including a 90.5% disease control rate in third-line NSCLC patients receiving ateganosine followed by cemiplimab.

90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient

07/17/2026

Initial efficacy findings from Part C of MAIA Biotechnology's Phase 2 THIO-101 expansion trial were consistent with the encouraging efficacy signals previously reported for Parts A and B, despite evaluating a more heavily pre-treated third-line NSCLC patient population.

Part C included patients who had previously received docetaxel and demonstrated resistance to both immunotherapy and other chemotherapies.

Learn more: https://bit.ly/4h3mBtz

07/08/2026

MAIA Biotechnology (NYSE: MAIA) reported positive initial efficacy data from Part C of its Phase 2 THIO-101 trial evaluating ateganosine in third-line NSCLC.

The efficacy-evaluable population achieved a 90.5% disease control rate with ateganosine followed by cemiplimab, with initial observations aligning with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population.

Learn more: https://bit.ly/4h3mBtz

06/30/2026

As MAIA Biotechnology advances the clinical development of ateganosine as a third-line treatment for advanced NSCLC, recent milestones continue to support progress across both Phase 2 and Phase 3 programs.

A recent Channelchek report highlighted enrollment progress, clinical site expansion, and other developments that contributed to a productive June for the company.

Dive in: https://bit.ly/4fbkSB6

06/25/2026

MAIA Biotechnology (NYSE: MAIA) has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine in advanced NSCLC patients receiving third-line therapy.

A total of 41 patients have been enrolled and treated across international clinical sites in Taiwan, Turkey, Poland, Hungary, Romania, and Georgia. Patient screening remains ongoing at three activated clinical sites in the United States.

The THIO-101 trial continues to evaluate ateganosine, MAIA's investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers.

Learn more: https://bit.ly/4etBeF5

06/25/2026

MAIA Biotechnology's ongoing THIO-101 expansion trial is evaluating ateganosine as a third-line treatment for patients with advanced (NSCLC.

The Phase 2 study continues to enroll patients previously treated with checkpoint inhibitors and chemotherapy as MAIA advances its clinical research efforts.

Read the latest update: https://bit.ly/3PVZA0O

06/22/2026

MAIA Biotechnology's lead investigational therapy, ateganosine, is designed to target telomeres in cancer cells while also inducing immune activation.

The therapy is currently being evaluated in the company's Phase 3 THIO-104 clinical trial for advanced NSCLC, supporting MAIA's focus on developing innovative approaches in oncology.

Learn more: https://bit.ly/43ekpYo

06/18/2026

MAIA Biotechnology (NYSE: MAIA) has opened enrollment at Winship Cancer Institute of Emory University, the third U.S. clinical site participating in the Phase 2 THIO-101 expansion trial evaluating ateganosine as a third-line treatment for NSCLC.

Winship is Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is recognized for its leadership in cancer innovation, discovery, and clinical research.

Learn more: https://bit.ly/44gbh5J